Faron Pharmaceuticals Oy has announced the appointment of Dr. Juho Jalkanen as the Chief Executive Officer of the company, effective from the first of May 2024. Dr. Jalkanen, who has been serving as the Chief Operating Officer of Faron Pharmaceuticals since 2022, brings a wealth of experience to his new role. He has worked at Faron in various capacities since 2006, including as Deputy Member of the Board, Director, and Chief Development Officer. Dr. Jalkanen has a background in medicine, having served as a Specialist Consultant in Vascular Surgery at Turku University Hospital. He holds an MSc in International Business Administration & Economics, an MD, and a PhD in Molecular Medicine and Vascular Surgery.

Dr. Jalkanen's appointment as CEO comes at a crucial time for Faron Pharmaceuticals as the company advances its bexmarilimab development program and approaches key milestones. Tuomo Patsi, Chairman of the Board of Faron Pharmaceuticals, expressed his confidence in Dr. Jalkanen's ability to lead the company, stating, "Juho has demonstrated his abilities in his prior roles at Faron and is well positioned to lead the company in its mission to bring the promise of immunotherapy to more patients."

In addition to his new role, Dr. Jalkanen has an interest in 1,023,888 ordinary shares in the company, approximately 1.42% of the company's issued share capital, and holds 232,270 options in the company. The announcement clarified that Dr. Jalkanen was appointed as CEO but not to the Board of the Company, amending the previous announcement that stated he was appointed as director and CEO.

Faron Pharmaceuticals is known for its investigational immunotherapy, Bexmarilimab, which is designed to overcome resistance to existing treatments and optimize clinical outcomes by targeting myeloid cell function and igniting the immune system. The therapy aims to reprogram macrophages from an immunosuppressive state to an immunostimulatory one, priming the immune system to attack tumors and sensitizing cancer cells to standard care.

For more information, interested parties can contact Faron Pharmaceuticals directly or its investor contacts at LifeSci Advisors and ICR Consilium. The company's financial advisers and broker details are also provided for further inquiries.